

Regulation of miRNAs on c-met protein expression in ovarian cancer and its implication

H. LIU¹, S.-R. LI², Q. SI³

¹Departments of Pathology, The Affiliated Hospital of Inner Mongolia Medical University, The Inner Mongolia Autonomous Region Tumor Hospital, The Inner Mongolia Autonomous Region Hohhot, China.

²Pathological Staff Room, Inner Mongolia Medical University, The Inner Mongolia Autonomous Region Hohhot, China.

³Departments of Gynecologic Oncology, The Affiliated Hospital of Inner Mongolia Medical University, The Inner Mongolia Autonomous Region Tumor Hospital, The Inner Mongolia Autonomous Region Hohhot, China.

Hui Liu and Shi-Rong Li contributed equally

Abstract. – **OBJECTIVE:** HGF/c-met signal pathway exerts important roles in tumor pathogenesis. The study of c-met related regulatory mechanism provides the basis for finding anti-tumor molecular drugs. MiRNAs can effectively regulate gene expression and work as cancer therapy. The identification of miRNAs for c-met regulation and study of related mechanism is of critical importance.

MATERIALS AND METHODS: Bioinformatics approach was used to search for possible miRNAs with regulatory function on c-met gene. Using pcDNA3.1-EGFP as scaffold, miRNAs over-expression and inhibition plasmids were constructed for electroporation transfection in ovarian cell line ES-Ovar. pcDNA3.1-EGFP empty plasmid was used as the control group. qRT-PCR and Western blot were applied to measure c-met mRNA and protein expression, followed by transwell chamber invasion assay for the evaluation of invasion potential.

RESULTS: Bioinformatics prediction showed favorable regulatory function of c-met gene by miR-204. The differential expressions of EGFP were observed between pcDNA3.1-EGFP-204-up and pcDNA3.1-EGFP-204-down plasmids. After transfection for 24 h and 48 h, c-met expression in miR-204 over-expression group was significantly down-regulated ($p < 0.05$ compared to control group), accompanied with reducing cell migration and invasion potency in a time dependent manner ($p < 0.05$). In contrast, no significant difference in level of c-met was found in the inhibition group and control group ($p > 0.05$).

CONCLUSIONS: The up-regulation of miR-204 down-regulated the expression of c-met in ovarian cancer cells and inhibited cell infiltration. The

study showed that miR-204 expression, however, presented significant impact on cell infiltration potential.

KEYWORDS: miR-204, Ovarian cancer, Cell migration, Cell infiltration.

Introduction

Ovarian cancer is the most common and deadly malignant tumor in females, the incidence of which has been gradually increasing in recent years. About 70% of ovarian cancer cases belong to moderate to terminal stage once being diagnosed, presenting severe threats to public health¹⁻³. The study showed that ovarian cancer pathogenesis was affected by various factors, including environment and genetics. With advancement of medical science and laboratory methods, early diagnosis of ovarian cancer has become feasible at present, and it largely decreases overall mortality. However, major treatment approaches against ovarian cancer still depend on chemotherapy or radiotherapy^{4,5}. The development of biotechnology and genetic engineering has provided novel insights for tumor treatment. The study of differential gene expressions during tumor pathogenesis can benefit individualized treatment and drug delivery, thus making it critical to find effective target gene in cancer therapy^{6,7}.

Normal HGF/c-Met signal pathway predominantly participated in the regulation of embryonic development and angiogenesis, and its abnormal activation was closely correlated with tumor pathogenesis and metastasis. Currently, anti-tumor drugs targeting this signal pathway have obtained major effects^{8,9}. This pathway mainly included the activation of intracellular tyrosine kinase phosphorylation via binding between HGF and c-met, further regulating multiple downstream signal pathways containing PI3K, ERK1/2 and FAK, thus modulating various biological functions of tumor cells¹⁰. A previous research showed that up-regulation of c-met could decrease cell-to-cell adhesion and facilitate cell metastasis¹¹, suggesting the possibility of using the inhibitors of c-met gene and related factors/genes as novel treatment targets. MiRNA has potent regulatory effects on target gene expression, and becomes the research focus in current biological treatment. It is widely distributed in cells and tissues, and exerts the regulatory function via complete complementary binding with target genes to directly degrade target gene mRNA or block gene translation at post-transcriptional stage or translational stage. In this regard, miRNA exerted its function as oncogene and tumor suppressor gene to regulate biological behaviors including cell proliferation or apoptosis, and exhibited close correlation with tumor onset and progression^{12,13}. Current technology of miRNA study has gained advances as the findings of its important regulatory roles in multiple human diseases and some miRNAs have become markers for tumor diagnosis or targets for clinical drugs. In this work, we aimed to illustrate the effect of miR-204 on ovarian cancer and related regulatory mechanism.

Materials and Methods

Major Equipment and Materials

Human ovarian cancer cell line ES-2 was purchased from Puro Biotech (Shanghai, China) and was reserved in our department. Dulbecco's Modified Eagle's Medium (DMEM)/F12 medium, fetal bovine serum and trypsin were purchased by Sigma-Aldrich (St. Louis, MO, USA). Trypsin and transwell chamber with Matrigel were produced by BD Biosciences (Franklin Lakes, NJ, USA). Phosphate buffered saline (PBS) and dual antibiotics were purchased from Tiangen Bio (Beijing, China). Lipofectamine transfection reagent, SYBR fluorescent

dye, cDNA synthesis kit were purchased from Promega (Madison, WI, USA). Human β -actin antibody from mouse polyclonal and goat polyclonal secondary antibody were purchased from Xinlei Bio (Shanghai, China). Western blot reagents were produced by Beyotime (Beijing, China). pcDNA3.1-EGFP plasmid was purchased from You Bio (Changsha, Hunan, China). Restriction endonucleases were produced by Takara (Otsu, Shiga, Japan). Electroporation transfection reagent and equipment were produced by Loza (Encino, CA, USA). Fluorescent quantitative PCR cycle was produced by ABI (Foster, CA, USA). Microplate reader was a product of Thermo-Fisher Scientific (Framingham, MA, USA).

Gene Sequence Analysis and Plasmid Construction

Based on human c-met gene sequence accessed from NCBI (NM_00245.3), TargetScan Human was used to predict and to analyze possible regulatory miRNAs. Results showed that miR-204 had the highest score of 84.2. Based on miR-204 sequence, NEB cutter (http://nc2.neb.com/NEBcutter2/) was used to analyze enzymatic digestion site on gene sequence. NotI and XhoI restriction sites were introduced on upstream and downstream. Sense and anti-sense sequences of pre-miR-204 were synthesized by Invitrogen (Carlsbad, CA, USA) with length of 263bp. Using pcDNA3.1-EGFP as the plasmid scaffold, dual enzymatic digestion was used to construct miR-204 over-expression and inhibitor plasmids. PCR method was used to investigate construction of plasmid, using forward primer (5'-CTAGA GAACC CACTG CTTAC-3') and reverse primer (5'-TAGAA GGCAC AGTCG AGG-3') under 95°C 5 min, followed by 30 cycles each containing 95°C 30 s, 55°C 35 s and 72°C 30 s. Those plasmids after positive screening were sequenced for selecting those targets for further study.

Cell Culture and Transfection

Human ovarian cancer cells ES-2 were resuscitated by routine method, and were cultured in DMEM medium containing 10% FBS and 1% dual antibiotics in a 37°C chamber with 5% CO₂ for 24 h. PBS buffer was used for rinsing cells repeatedly. Cells were digested with trypsin for 2-3 min until becoming shrinkage to rounding. Serum-containing medium was introduced to stop the digestion. Cell suspension was saved and centrifuged at 400 g for 3 min. The supernatant was discarded, with the addition of fresh medium for repeating rinsing to

prepare single cell suspension. Cells were counted and transferred to 60 mm dish at 1×10^6 density for 24 h incubation. Cell transfection was performed when reaching 90% confluence with covering the dish bottom. Transfection plasmid concentration was set as 5 μ g using 250 V electrical filed for 5 ms. After transfection, cell suspension was transferred to 6-well plate for culture using pcDNA3.1-EGFP empty plasmid as the control group. Transfection efficiency was deduced by the expression of green fluorescence. Single cell colony was collected for further culture.

qRT-PCR for miR-204 Expression in Cells Before and After Transfection

Following the manual instruction of RNA extraction and cDNA synthesis kit, total RNA was extracted from cells at 24 h or 48 h after transfection, followed by cDNA synthesis. qRT-PCR was used to detect miR-204 expression, using forward primer (5'-GGCTA CAGTC TTTCT TCAT-3') and reverse primer (5'-GCCAG TGA-TG ACAAT TG-3'). GAPDH was used as the internal reference (forward primer: 5'-CGGAG TCAAC GGATT TGGTC GTA-3'; reverse primer: 5'-AGCCT TCTCC ATGGT GGTG-3'). In a 20 μ L qRT-PCR system, 10 μ L PCR pre-mixture, 0.6 μ L primer mixture, 0.8 μ g cDNA and nuclease-free water were added and mixed. PCR was performed under the following conditions: 95°C for 2 min, followed by 35 cycles each containing 95°C 10 s, 55°C 30 s and 72°C 10 s, ended with 95°C 1 min, 60°C 30 s and 72°C 30 s. Each group was tested in triplicate. Relative values to reflect miR-204 expression were calculated.

Western Blot for c-met Expression in Cells Before and After Transfection

Total cellular proteins were collected at 24 h or 48 h after transfection. 1 mL of culture medium was removed and cells were washed by PBS for 3-5 times. Cells were then mixed with lysis buffer containing protease inhibitor and phosphatase inhibitor for 25 min iced incubation. Lysate was saved and centrifuged at 10000 g under 4°C for 15 min. Supernatant was saved and quantified using protein assay kit using BCA method. Protein samples were separated by 10% separating gel, and then transferred to PVDF membrane using semi-dry method (35 V, 30 min). The membrane was blocked using 5% bovine serum albumin (BSA) for 2 h room temperature incubation, followed by 4°C incubation in 1:200 diluted primary antibody. The membrane was washed by PBS

and Twee 20 (PBST), and was cultured with secondary antibody for 2 h using 1:500 diluted secondary antibody. Using β -actin as the internal reference, expression of c-met protein was measured.

Scratch Assay for the Effect of miR-204 Transfection on Cell Migration

After transfection for 24 h, when cells covered all over dish bottom, a sterile 200 μ L pipette tip was used to draw vertical lines on the dish bottom. Detached cells were washed by PBS for 2-3 times. Culture medium was then removed for 24 h incubation. Three scratch wounds were randomly selected under 200 $\times$ microscope for imaging to evaluate the migration distance among all groups.

Transwell Assay for Cell Invasion Potency

Cells were diluted in serum-free culture medium at 1:5 ratio, and was added into the chamber (100 μ L each), which was air-dried under 4°C. 24 h after transfection, cells were digested by trypsin and prepared for single cell suspension using medium containing 10% FBS. Cells were counted and seeded into the chamber with matrix gel pavement at 1×10^5 /ml. The chamber was incubated for 24 h, and was washed three times in PBS. Cells were fixed in paraformaldehyde and stained. Three fields were randomly selected for imaging under an inverted microscope for counting.

Statistical Analysis

Data were statistically analyzed by SPSS 11.3 (SPSS Inc., Chicago, IL, USA) and express as means $\pm$ standard deviation (SD). Student *t*-test was used to test significant difference between groups. Statistical significance was defined when $p < 0.05$, whilst extreme significance was defined when $p < 0.01$.

Results

Plasmid Construction and Confirmation

By dual enzymatic digestion and directed ligation, three plasmids were randomly selected for PCR assay. As shown in Figure 1, all plasmids included positive cloning, indicating successful construction of the plasmids. No mutation or missing of base pair was found after sequencing, suggesting that they can be used for further study.

Observation of cell Transfection

Cells were transfected by plasmids pcDNA3.1-EGFP, pcDNA3.1-EGFP-204-up and pcD-




Figure 1. PCR for plasmid construction. M, DNA marker; Lane 1-3, pcDNA3.1-EGFP-204-up; Lane 4-6, pcDNA3.1-EGFP-204-down.

NA3.1-EGFP-204-down. GFP expression was observed under an inverted fluorescent microscope. As shown in Figure 2, the expression of GFP in all three groups was shown at 24 h after transfection.

qRT-PCR for miR-204 Expression in Cells After Transfection

Total RNA was extracted at 24 h and 48 h post-transfection. The level of miR-204 was detected by using qRT-PCR. As shown in Figure 3, after transfection for 24 h or 48 h, miR-204 expression in pcDNA3.1-EGFP-204-up group was gradually elevated, whilst the level was decreased in pcDNA3.1-EGFP-204-down group ($p<0.05$ at 24 h post-transfection, and $p<0.05$ at 48 h post-transfection compared to pcDNA3.1-EGFP control group), suggesting that those two plasmid vectors could effectively mediate miR-204 expression.

Western Blot for c-met Protein Expression in Cells After Transfection

After 24 h and 48 h transfection, intracellular c-met protein expression was measured by Western blot. As shown in Figure 4A and Figure 4B of gray value analysis, c-met expression in pcDNA3.1-EGFP-up group gradually increased at 24 h post-transfection ($p<0.05$ compared to other groups). The expression of c-met in pcDNA3.1-EGFP-204-down group was marginally increased but showed no significant difference compared to pcDNA3.1-EGFP control group ($p>0.05$).

Transwell Chamber in vitro Assay for Cell Invasion

Cells after transfection were continuously cultured for 24 h. After stained with crystal violet (Figure 5), cells were counted and invasion percentage was calculated (Table I). Compared to pcDNA3.1-EGFP group, cells in pcDNA3.1-EGFP-204-up group presented significantly lower invasion rate (45.17%, $p<0.05$ compared to control group). Cells in pcDNA3.1-EGFP-204-down group showed invasion rate of 94.17%, indicating no significant difference comparing to control group ($p=0.652$).

Discussion

The occurrence of ovarian cancer represents an extremely complex process with family inheritance property, and is one of the three most common malignant tumors in female reproductive system, besides cervical cancer and uterus cancer. It leads to relatively high mortality and is associated




Figure 2. GFP expression at 24 h after transfection using pcDNA3.1-EGFP, pcDNA3.1-EGFP-204-up and pcDNA3.1-EGFP-204-down (10 $\times$).




Figure 3. qRT-PCR for miR-204 expression at 24 h and 48 h after transfection. *, $p < 0.05$ compared to control group; **, $p < 0.01$ compared to control group.

with multiple pathogenic factors. A direct factor is the change of cancer cell migration or infiltration potency, which severely threatens prognosis of patients with ovarian cancer¹⁵⁻¹⁷. Previous investigations showed that the pathogenesis process of tumor is frequently accompanied with over-expression of stem cell-related genes and factors, such as over-expression of c-met and COX-2/1 in breast cancer, lung cancer and ovarian cancer tissues^{18,19}. Through tyrosine kinase activity, c-met expression can affect cell adhesion, and its over-expression can facilitate cell migration and invasion. Via the binding with HGF for protein phosphorylation, it can activate various signal pathways of tumors, such as Ras, MAPK, PI3K and JAK/STAT, thus regulating tumor cell proliferation, differentiation, migration and infiltration potency. Therefore, the HGF/c-met signal pathway plays a vital role in the occurrence and progression of many tumors. The study of this pathway has been the hot-spot for tumor targeting therapy. The study confirmed that in normal cells, the expression of c-met was observed at a low level to maintain the homeostasis. Under the circumstance of tumor formation, c-met immediately formed abnormal high expression. Therefore, the blockade of HGF/c-met pathway and decrease of c-met expression demonstrated an effective measure to inhibit further progression of tumor. The study of c-met in tumor cell expression and its regulatory mechanism provided it




Figure 4. Western blot for c-met expression in all groups after transfection. *, $p < 0.05$ compared to control group; **, $p < 0.01$ compared to control group.

as an effective biological treatment target in clinics. MiRNAs exerted regulatory function in proliferation, apoptosis, and migration of various cancer cells. For instance, miR-34 regulated cancer cell behaviors via mediating p53 signal pathway, whilst miR-21 and miR-27a affected liver cancer pathogenesis and progression via expression of tumor suppressor gene sprouty 2 in liver tissues²⁰⁻²³. This work utilized bioinformatics approach to analyze c-met stem cell like gene, and searched for potential miRNAs targeting c-met. MiR-204 was revealed to possess multiple functional targets to c-met gene, with the highest score among miRNAs. Previous reports showed that miR-204 was involved in progression of multiple tumors including cervical cancer, kidney cancer and ovarian cancer. In this study, the effect of miR-204 was evaluated by overexpression or reduction of

Table 1. Transwell chamber assay for cell invasion rate.

	Invasion cell number per field	Invasion rate (%)	<i>p</i>
pcDNA3.1-EGFP	53.344		
pcDNA3.1-EGFP-204-up	24.532	45.98	0.001
pcDNA3.1-EGFP-204-down	50.236	94.17	0.652




Figure 5. Transwell assay at 24 h after transfection.

miR-204. We constructed miR-204 over-expression or inhibition vectors using pcDNA3.1-EGFP as the scaffold. PCR and sequencing were used to identify ovarian cancer cell line ES-2 with correct transfection, followed by qRT-PCR and Western blot to measure mRNA and protein expression of c-met at 24 h or 48 h post-transfection. Transwell chamber assay was used to determine invasion potency of cells. The effect of miR-204 on c-met expression at the cellular level was also investigated. Results showed that our constructed miR-204 over-expression and inhibitor plasmids all effectively facilitated or inhibited miR-204 expression, respectively. Furthermore, we showed that over-expression of miR-204 significantly suppressed expression of c-met, whilst down-regulation had no significant effect on c-met expression. This is probably due to multiple mechanisms regulating c-met, or because of the homeostatic mechanism of c-met level.

Conclusions

miR-204 effectively suppressed the expression of c-met in ovarian cancer cell ES-2 can, further improve cell migration or infiltration potency.

Acknowledgements

This work was supported by The Inner Mongolia Autonomous Region Natural Science Foundation (2015YF020027).

Conflict of interest

The authors declare no conflicts of interest.

References

- BERGAMINI A, PIRRO C, DI NAPOLI M, ARENARE L, DELLA PEPA C, TAMBALONE F, FACCHINI G, GARGIULO P, ROSSETTI S, MANGILI C, MANATA S, CECERE SC. Cisplatin can be safely administered to ovarian cancer patients with low tumor sensitivity to carboplatin. *Gynecol Oncol* 2016; 122: 72-76.
- HUANG L, JIN Y, FENG S, ZOU Y, XU S, QIU S, LI L, ZHENG J. Role of Wnt/beta-catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca2+ pathways in cisplatin-induced chemoresistance in ovarian cancer. *Exp Ther Med* 2016; 12: 3851-3858.
- GRUNEWALD T, LEDERMANN JA. Targeted therapies for ovarian cancer. *Best Pract Res Clin Obstet Gynaecol* 2017; 41: 139-152.
- KEENAN M, TATE TH, KIEU K, BLACK JF, UTZINGER U, BARTON JK. Design and characterization of a combined OCT and wide field imaging fallopiscope for ovarian cancer detection. *Biomed Opt Express* 2017; 8: 124-136.
- KRISHNAN V, BERK JS, DORIGO O. Immunotherapy in ovarian cancer. *Curr Probl Cancer* 2017; 41: 48-63.
- LV XL, ZHU Y, LIU JW, AI H. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer. *Eur Rev Med Pharmacol Sci* 2016; 20: 5113-5116.
- LI YP, YANG JJ, XU H, GUO EY, YU Y. Structure-function analysis of DNA helicase HELQ: a new diagnostic marker in ovarian cancer. *Oncol Lett* 2016; 12: 4439-4444.
- BRADLEY CA, DUNNE PD, BINGHAM V, McQUAID S, KHAWAJA H, CRAIG S, JAMES J, MOORE WL, McART DG, LAWLER M, DASGUPTA S, JOHNSTON PG, VAN SCHAEYBROECK S. Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. *Oncotarget* 2016; 7: 78932-78945.
- JIAO D, WANG J, LU W, TANG X, CHEN J, MOU H, CHEN QY. Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met de-

- pendent PI3K/Akt/mTOR signaling pathways in lung cancer. *Mol Ther Oncolytics* 2016; 3: 16018.
- 10) KWON Y, GODWIN AK. Regulation of HGF and c-MET interaction in normal ovary and ovarian cancer: importance of targeting c-MET and HGF interaction. *Reprod Sci* 2017; 24: 494-501.
 - 11) MIAO L, LU Y, XU Y, ZHANG G, HUANG Z, GONG L, FAN Y. PD-L1 and c-MET expression and survival in patients with small cell lung cancer. *Oncotarget* 2016; doi: 10.18632/oncotarget.9765. [Epub ahead of print]
 - 12) JIANG J, FENG X, ZHOU W, WU Y, YANG Y. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway. *Oncotarget* 2016; 7: 73188-73199.
 - 13) CHEN QY, JIAO DM, WU YQ, CHEN J, WANG J, TANG XL, MOU H, HU HZ, SONG J, YAN J, WU LJ, CHEN J, WANG Z. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3K/Akt/mTOR pathway. *Oncotarget* 2016; 7: 18247-18261.
 - 14) LI B, YANG XX, WANG D, JI HK. MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met. *Eur Rev Med Pharmacol Sci* 2016; 20: 1109-1114.
 - 15) WU JC, WANG CT, HUNG HC, WU WJ, WU DC, CHANG MC, SUNG PJ, CHOU YW, WEN ZH, TAI MH. Noteremin is a novel c-Met/STAT3 inhibitor in advanced prostate cancer cells. *Prostate* 2016; 76: 1469-1483.
 - 16) WEI W, LI Y, LV S, ZHANG C, TIAN Y. PARP-1 mediated involved in angiogenesis in epithelial ovarian cancer. *Oncol Lett* 2016; 12: 4561-4567.
 - 17) WANG F, LI S, ZHAO Y, YANG K, CHEN M, MAO J, LUO Y, TANG W, SHENG M. Predictive value of overexpression for CXCR4, C-Met and VEGF among breast cancer patients: a meta-analysis. *Breast* 2016; 28: 45-53.
 - 18) XU J, FOOTMAN A, QIN Y, AYSOLA M, REDDY V, SINGH K, GRIZZLE W, YOU S, MOELLERIN, REDDY ES, FU Y, RAO VN. BRCA1 mutation leads to upregulated ubc9 levels which triggers proliferation and migration of patient derived high grade serous ovarian cancer and triple negative breast cancer cells. *Int J Chron Dis Ther* 2016; 2: 31.
 - 19) YANG Y, ZHAO L, LI X, ZHANG Z, LI J. Effects of anti-CD44 monoclonal antibody IM7 conjugated with chitosan poly(lactic acid-co-glycolic acid) particles on the treatment of ovarian cancer. *Oncol Lett* 2017; 13: 99.
 - 20) YU C, CHEN P, CHEN CY, YU CH, CHOU MY. Suppression of miR-21 in oral squamous cell carcinomas to promote cancer stemness, EMT and lymph node metastasis. *Oncotarget* 2016; 7: 20180-20192.
 - 21) YE S, LI J, HAN Y, YAN J, ZHOU H. The efficacy and risk profile of EGFR inhibitors in non-small cell lung cancer: a meta-analysis. *Sci Rep* 2016; 6: 35770.
 - 22) CHEN S, MURRAY K. Gene-microRNA network model for ovarian cancer. *BMC Syst Biol* 2016; 10: 117.
 - 23) YUNUSOVA NV, VILLERT AB, SPIRINA LV, FROLOVA AE, KONDAKOVA IV. Insulin-like growth factors and their binding proteins in tumors and ascites of ovarian cancer patients: association with response to neoadjuvant chemotherapy. *Asian Pac J Cancer Prev* 2016; 17: 6215-6220.